Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts on Tuesday, 8 September, from 13:30 to 17:00 UK time at the London Stock Exchange. The event will be available via live webcast, with in-person attendance by invitation only on a first-come, first-served basis. Details on accessing the webcast can be found here.
The capital markets day comes as Sandoz emphasizes its position in the biosimilars market, which the company describes as entering a 'golden decade.' With its leading portfolio of approximately 1,300 medicines and net sales of USD 11.1 billion in 2025, Sandoz aims to demonstrate how it plans to maximize shareholder value through its biosimilars pipeline and global reach. The event will feature presentations from senior management, covering strategic priorities, financial targets, and growth drivers.
In addition, Sandoz plans to host an investor and analyst site visit in Slovenia from 9-10 November, providing insight into its new biosimilars development and supply-chain hub. Attendance will also be by invitation only, and the site visit will not be webcasted. This follows Sandoz's 20-year legacy in biosimilars, which it celebrates in 2026 alongside 80 years of antibiotics manufacturing and 140 years of heritage.
The announcements underscore Sandoz's commitment to expanding access to affordable biologics, a key growth area as patents on many biologic drugs expire. With over 20,000 colleagues of 100 nationalities, Sandoz reaches more than one billion patients globally, generating substantial healthcare savings. The capital markets day and site visit are expected to provide deeper insights into how the company intends to capitalize on market opportunities and regulatory tailwinds.
Forward-looking statements in the release caution that actual outcomes may vary due to risks including global economic conditions, exchange rates, and competitive activities. Sandoz undertakes no obligation to update these statements except as required by law.
